» Articles » PMID: 25961460

MicroRNA-26a Regulates Insulin Sensitivity and Metabolism of Glucose and Lipids

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2015 May 12
PMID 25961460
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes (T2D) is characterized by insulin resistance and increased hepatic glucose production, yet the molecular mechanisms underlying these abnormalities are poorly understood. MicroRNAs (miRs) are a class of small, noncoding RNAs that have been implicated in the regulation of human diseases, including T2D. miR-26a is known to play a critical role in tumorigenesis; however, its function in cellular metabolism remains unknown. Here, we determined that miR-26a regulates insulin signaling and metabolism of glucose and lipids. Compared with lean individuals, overweight humans had decreased expression of miR-26a in the liver. Moreover, miR-26 was downregulated in 2 obese mouse models compared with control animals. Global or liver-specific overexpression of miR-26a in mice fed a high-fat diet improved insulin sensitivity, decreased hepatic glucose production, and decreased fatty acid synthesis, thereby preventing obesity-induced metabolic complications. Conversely, silencing of endogenous miR-26a in conventional diet-fed mice impaired insulin sensitivity, enhanced glucose production, and increased fatty acid synthesis. miR-26a targeted several key regulators of hepatic metabolism and insulin signaling. These findings reveal miR-26a as a regulator of liver metabolism and suggest miR-26a should be further explored as a potential target for the treatment of T2D.

Citing Articles

Identifying insulin-responsive circRNAs in chicken pectoralis.

Shao B, Wang Z, Luo P, Du P, Zhang X, Zhang H BMC Genomics. 2025; 26(1):148.

PMID: 39955508 PMC: 11830218. DOI: 10.1186/s12864-025-11347-w.


Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model.

Schutz F, Longo L, Keingeski M, Filippi-Chiela E, Uribe-Cruz C, Alvares-da-Silva M World J Hepatol. 2025; 16(12):1468-1479.

PMID: 39744199 PMC: 11686535. DOI: 10.4254/wjh.v16.i12.1468.


Could chronic opioid use be an additional risk of hepatic damage in patients with previous liver diseases, and what is the role of microbiome?.

Tarantino G, Cataldi M, Citro V Front Microbiol. 2024; 15:1319897.

PMID: 39687876 PMC: 11646994. DOI: 10.3389/fmicb.2024.1319897.


The Role of Hypothalamic Microglia in the Onset of Insulin Resistance and Type 2 Diabetes: A Neuro-Immune Perspective.

Darwish R, Alcibahy Y, Bucheeri S, Albishtawi A, Tama M, Shetty J Int J Mol Sci. 2024; 25(23).

PMID: 39684879 PMC: 11642714. DOI: 10.3390/ijms252313169.


MiR-26a Inhibits Porcine Adipogenesis by Regulating ACADM and ACSL1 Genes and Cell Cycle Progression.

Zhang D, Hao W, Zhu R, Wang L, Wu X, Tian M Animals (Basel). 2024; 14(23).

PMID: 39682455 PMC: 11640176. DOI: 10.3390/ani14233491.


References
1.
Beale E, Hammer R, Antoine B, Forest C . Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol Metab. 2004; 15(3):129-35. DOI: 10.1016/j.tem.2004.02.006. View

2.
Dong B, Saha P, Huang W, Chen W, Abu-Elheiga L, Wakil S . Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A. 2009; 106(44):18831-6. PMC: 2773998. DOI: 10.1073/pnas.0909731106. View

3.
Siomi H, Siomi M . Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010; 38(3):323-32. DOI: 10.1016/j.molcel.2010.03.013. View

4.
Ellis J, Frahm J, Li L, Coleman R . Acyl-coenzyme A synthetases in metabolic control. Curr Opin Lipidol. 2010; 21(3):212-7. PMC: 4040134. DOI: 10.1097/mol.0b013e32833884bb. View

5.
Voight B, Scott L, Steinthorsdottir V, Morris A, Dina C, Welch R . Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42(7):579-89. PMC: 3080658. DOI: 10.1038/ng.609. View